SEC Form 4 · accession 0001209191-19-011489
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bowden
Officer — Chief Medical Officer
Period of report
Feb 16, 2019
Accepted (ET)
Feb 20, 2019 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1,F2 | Feb 16, 2019 | M | 2,750 | — | A | 8,013 | D | |
| Common stock | Feb 19, 2019 | F | 818 | $58.03 | D | 7,195 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitF1,F3 | — | Feb 16, 2019 | M | 2,750 | D | — | — | Common stock | 2,750 | 5,500 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2Includes 34 shares purchased through the Company's employee stock purchase plan.
- F3The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.